Related Experiment Videos
Elevated serum prostate specific antigen (PSA) related to asymptomatic prostatic inflammation
L Hoekx1, W Jeuris, E Van Marck
1Department of Urology, University Hospital Antwerp, Belgium.
Acta Urologica Belgica
|December 29, 1998
Summary
Subclinical inflammation in the prostate, particularly aggressive forms, can lower the risk of missed prostate cancer in biopsies. Inflammation density alone does not correlate with prostate specific antigen (PSA) levels.
Area of Science:
- Urology
- Pathology
- Oncology
Background:
- Prostatic subclinical inflammation can elevate serum prostate specific antigen (PSA) levels.
- The relationship between inflammation characteristics and PSA requires further investigation for accurate prostate cancer diagnosis.
Purpose of the Study:
- To investigate the association between prostatic inflammation aggressiveness and serum PSA levels.
- To determine if inflammation characteristics influence the risk of missed prostate cancer on biopsy.
Main Methods:
- Grading prostatic inflammation aggressiveness on a 4-point scale.
- Analyzing the correlation between inflammation scores, PSA levels, and biopsy results.
- Evaluating the density of inflammatory cells in prostatic tissue.
Main Results:
- Elevated serum PSA is linked to prostatic inflammation with glandular epithelial disruption.
- High aggressiveness scores in prostatic inflammation correlate with a reduced risk of biopsy-missed prostate cancer.
- The density of inflammatory cells in prostate tissue does not correlate with serum PSA levels.
Conclusions:
- Prostatic inflammation aggressiveness is a crucial factor in interpreting elevated PSA levels.
- Considering both inflammation aggressiveness and PSA is vital for accurate prostate biopsy interpretation.
- This approach may help reduce the risk of missed prostate cancer diagnoses.